Results 161 to 170 of about 22,865 (199)
Some of the next articles are maybe not open access.
Biochemistry of the non-mevalonate isoprenoid pathway
Cellular and Molecular Life Sciences, 2011The non-mevalonate pathway of isoprenoid (terpenoid) biosynthesis is essential in many eubacteria including the major human pathogen, Mycobacterium tuberculosis, in apicomplexan protozoa including the Plasmodium spp. causing malaria, and in the plastids of plants.
Gräwert, Tobias +4 more
openaire +3 more sources
Druggability of the enzymes of the non-mevalonate-pathway
Drug Discovery Today, 2013The non-mevalonate pathway constitutes a source of novel drug targets. This biosynthetic route is essential for pathogens but is absent in humans. Our systematic evaluation of the druggability of all enzymes provides a convenient way of selecting targets that should be most easily inhibited by small-molecule drugs.
Tiziana, Masini +2 more
openaire +2 more sources
Key Enzymes for the Mevalonate Pathway in the Cardiovascular System
Journal of Cardiovascular Pharmacology, 2021Abstract: Isoprenylation is an important post-transcriptional modification of small GTPases required for their activation and function. Isoprenoids, including farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate, are indispensable for isoprenylation by serving as donors of a prenyl moiety to small G proteins.
Chi, Zhang +4 more
openaire +2 more sources
Mevalonate pathway: A review of clinical and therapeutical implications
Clinical Biochemistry, 2007Mevalonate pathway is an important metabolic pathway which plays a key role in multiple cellular processes by synthesizing sterol isoprenoids, such as cholesterol, and non-sterol isoprenoids, such as dolichol, heme-A, isopentenyl tRNA and ubiquinone. While extensively studied in regard with cholesterol synthesis and its implications in cardiovascular ...
Hassane Izzedine
exaly +3 more sources
Mevalonate Kinase Deficiency: Disclosing the Role of Mevalonate Pathway Modulation in Inflammation
Current Pharmaceutical Design, 2012Inflammation is a highly regulated process involved both in the response to pathogens as well as in tissue homeostasis. In recent years, a complex network of proteins in charge of inflammation control has been revealed by the study of hereditary periodic fever syndromes.
A. Marcuzzi +5 more
openaire +3 more sources
Targeting the mevalonate pathway in multiple myeloma
Leukemia Research, 2010Multiple myeloma is an incurable plasma cell malignancy. Although novel agents have improved overall survival in the last decade, multidrug resistance eventually still occurs in all patients. New treatment strategies are therefore needed. Statins are HMG-CoA reductase inhibitors that are well known as treatment for hypercholesterolemia. In addition, in
openaire +2 more sources
A Biosynthetic Pathway to Isovaleryl‐CoA in Myxobacteria: The Involvement of the Mevalonate Pathway
ChemBioChem, 2005AbstractA biosynthetic shunt pathway branching from the mevalonate pathway and providing starter units for branched‐chain fatty acid and secondary metabolite biosynthesis has been identified in strains of the myxobacterium Stigmatella aurantiaca. This pathway is upregulated when the branched‐chain α‐keto acid dehydrogenase gene (bkd) is inactivated ...
Mahmud, T. +6 more
openaire +3 more sources
Metabolic Engineering of the Mevalonate and Non-Mevalonate Pathways in Tomato
2003In higher plants isoprenoids have many essential roles e.g. in membrane structure (phytosterols), redox chemistry (plastoquinone) and as antioxidants (carotenoids). Despite their functional and chemical diversity all isoprenoids are biosynthetically related from a common precursor, isopentenyl pyrophosphate (IPP).
E. M. Enfissi +5 more
openaire +1 more source
Biosynthesis of isoprenoids via the non-mevalonate pathway
Cellular and Molecular Life Sciences, 2004The mevalonate pathway for the biosynthesis of the universal terpenoid precursors, isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), is known in considerable detail. Only recently, the existence of a second mevalonate-independent pathway for the biosynthesis of IPP and DMAPP was detected in plants and certain eubacteria.
W, Eisenreich +3 more
openaire +2 more sources
Targeting mutant p53 through the mevalonate pathway
Nature Cell Biology, 2016It is well established that mutant forms of the p53 tumour suppressor acquire pro-oncogenic activities. Inhibition of the mevalonate pathway is now shown to promote degradation of select oncogenic mutant p53 proteins, indicating that destabilization of mutant p53 could be a promising therapeutic strategy.
William, Freed-Pastor, Carol, Prives
openaire +2 more sources